Clinical Trial Search

Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy — 1.55; -0.42 ratio

Primary: Number of Participants With Adverse Events — 3; 1; 1; 1 participants

Primary: Percent of Patients Who Achieved PCDAI Response — 78.6; 100.0; 100.0; 92.9 percentage of participants

Primary: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine — -0.1; 9.5 percent change — p=<0.001

Primary: Central Sensitization — 463.5; 383.6; 425.7; 358.0 kilopascal — p=0.44

Primary: Number of Participants With PASI 90 Response at Week 32 — 93; 105 participants — p=0.087

Primary: Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment — 32.67; 51.72 percentage of days — p=0.057

Primary: Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI) — 304; 349 Participants

Primary: The Distribution of Children With Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan — 12; 22; 111; 109 Participants — p=0.16

Primary: Number of Participants With American College of Rheumatology 20 (ACR20) Response — 47; 45; 21 Participants — p=0.0002

Primary: Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -5.81; -6.97 score on a scale — p=0.53

Primary: Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) — 123; 620 Participants

Primary: CAPS-IV at the End of Treatment — 52.42; 50.61; 54.20; 48.59 units on a scale

Primary: Survival at Day 14 After Start of Intervention — 58; 260 Participants

Primary: Number of Subjects With at Least One Incidence of Treatment-Emergent Adverse Events (TEAEs) During the Study — 19 Participants